Cabozantinib Net Revenue for Q3 is $96.4 million.
Total Revenue of $152.5 million
Net Income of $81.4 million, Diluted EPS $0.26 per Share
Have these headlines said it all?
Of course not, but what they said was sufficient to appreciate this firm when compared to other firms that were granted approvals more than three to four years ago, yet they are still spending much than what they earn.
Exelixis’ (EXEL) drug Cabometyx is a tablet version of cabozantinib for patients with advanced renal cell carcinoma (RCC . . .